At the IGTP TODAY
A study led by IGTP researchers shows that, in a laboratory model, delafloxacin inhibits the intracellular replication of Legionella more effectively than a current standard treatment, supporting its potential therapeutic value and the need for future clinical studies.
Work-related factors play a significant and independent role in the risk of developing Long-COVID, shows a new study based on the COVICAT cohort and led by ISGlobal, in collaboration with the University of Turin and the IGTP. The findings, published in BMJ Occupational & Environmental Medicine, highlight that a substantial share of Long-COVID could be prevented through targeted workplace measures and policies.
On 11 December, IGTP celebrated its 30th anniversary with an institutional and Christmas event that brought together professionals from across the Institute in a space for recognition, remembrance, and looking ahead to the future.
The III CARE Annual Meeting, held on 5 December at BCIN, brought together the cancer research community of the Can Ruti Campus for a day focused on scientific dialogue, interdisciplinarity and future strategy.
The closing event celebrated on 17 November highlighted the work carried out and strengthened the commitment to maintain and expand the synergies created within the framework of the Plan. IGTP has contributed to several collaborative projects, focused on type 2 diabetes, breast cancer and medical databases.
Researchers at IGTP have published an article analysing the therapeutic potential of extracellular vesicles derived from mesenchymal stem cells to address kidney injury, reviewing current evidence on how these vesicles can interact with renal tubular epithelial cells.
A team of researchers from IGTP and ICO has studied alterations in the KRAS gene in colorectal cancer by combining genomic analyses with a systematic review of targeted compounds and clinical trials. Their findings, published in the journal npj Precision Oncology, provide and updated overview to guide future advances in this cancer's treatment.
A research team has created the first humanised cellular model to study GATA2 deficiency, a rare genetic disorder that predisposes individuals to severe blood conditions such as myelodysplastic syndrome and leukaemia. The study shows that, although the initial GATA2 mutation weakens haematopoietic stem cells, it is additional mutations -particularly in the SETBP1 gene- that drive disease progression.
At the Campus Can Ruti Core Facilities Infoday, the Josep Carreras Leukaemia Research Institute and the Germans Trias i Pujol Research Institute showcased their scientific services and the support they can offer to research conducted both on the campus and externally. The event also featured the presentation of the new IGTP-IJC Joint Flow Cytometry Unit, which has one of the most advanced infrastructures in the EU, as well as the new IJC's Translational-PATH2CURE hub, which aims to accelerate the translation of scientific discoveries into treatments for patients.
The Talents Grants for the 2024 and 2025 editions have been granted by the Fundació Catalunya La Pedrera, supporting healthcare professionals in developing research projects that will lead to their doctoral theses. This initiative, originally created through a collaboration with the Research Institute and Hospital Germans Trias i Pujol, now also includes Hospital Clínic Barcelona, the Vall d'Hebron Institute of Oncology and Hospital de Bellvitge.
